Wanjia (HKG:0401) incurred an attributable loss of HK$712,000 in the six months ended Sept. 30, compared with an attributable profit of HK$1.3 million a year prior, a Wednesday Hong Kong bourse filing said.

Loss per share in the interim period was HK$0.0013, whereas the company had made earnings per share of HK$0.0022 in the year-ago period.

The pharmaceutical distribution company's revenue jumped 2.4% to HK$85.7 million in the fiscal first half from HK$83.7 million previously, driven by a higher revenue from the Hemodialysis business wing.